BenevolentAI Investor Day Presentation Deck slide image

BenevolentAI Investor Day Presentation Deck

UC Target Identification workflow Mechanism 1 4 Biological Question Disease Can we treat UC by reversing chronic inflammation of the colonic mucosa by targeting pathways in colon epithelial cells and tissue resident immune cells? Endpoint: What we will measure Sign Experimental validation Cell type Endoscopic Biopsy from UC patients 2 Target Identification Predictive algorithms ran over the curated knowledge graph to identify potential targets, aggregate findings and present the most relevant ones to DD scientists 200 Colonic mucosa tissue culture and compound treatment 3 Target assessment and validation tools presented scientific evidence allowing scientists to evaluate the rational and opportunity for progressibility ✔PDE10 has zero linkage to UC in all available biomedical literature PDE10 inhibition promoted an anti-inflammatory effect Inflammatory cytokine measurement Benevolent 56
View entire presentation